GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2008

Biological E. Gains Access to Production Technology from Heparinex and Choncept

  • Heparinex and Choncept entered into option and license agreements with Biological E. (BE), a biopharmaceutical company based in India. The agreement reportedly provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds.

    Heparinex is focused on development of novel recombinant synthesis of compounds for the anticoagulation market to replace the current heparin source of beef and other animal byproducts. Choncept works on the development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?